First-in-human pharmacokinetic, safety, and preliminary efficacy studies of single- and multiple-dose FRSW117, a novel PEGylated recombinant factor VIII-Fc fusion protein with an extended half-life, in patients with severe hemophilia A

首次在重型血友病A患者中开展了单剂量和多剂量FRSW117（一种新型聚乙二醇化重组因子VIII-Fc融合蛋白，具有延长的半衰期）的人体药代动力学、安全性和初步疗效研究。